Angiotensin II (ANG II), the effector hormone of the renin-angiotensin system (RAS), has been implicated in the pathophysiology and progression of heart failure. Therefore, the measurement of ANGII has become important to characterize the role of this neurohormone in heart failure. However, because ANG II has been difficult to measure, other components of the RAS have been measured to characterize ANG II production. The RAS components (e.g., renin, angiotensin I–converting enzyme [ACE], angiotensin II) have been measured with a variety of techniques. In this review, RAS physiology and the techniques used to measure the RAS components are discussed. In addition, the advantages and disadvantages of the RAS measurement methods are described.
Alderman MH
, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. 1997. Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients. Am J Hypertens10:1-8.
2.
Amos DJ
, White HD. 1997. Remodeling after myocardial infarction: An opportunity for early intervention. Basic Res Cardiol92:69-71.
3.
Annarosa YL
, Baosheng L, Wang X. 1998. Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes. Circ Res82:1145-1159.
4.
Anversa P
, Olivetti G, Capasso JM. 1991. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol68(14):7D-16D.
5.
Arnal JF
, Cudek P, Plouin PF, Guyenne TT. 1991. Low angiotensinogen levels are related to the severity and liver dysfunction of congestive heart failure: Implications for renin measurements. Am J Med90:17-22.
6.
Balcells E
, Meng QC, Johnson WH. 1997. Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. Am J Physiol273(4 Pt 2): H1769-H1774.
7.
Ball SG
, Julian DG, Murray GD. 1993. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet342:821-828.
8.
Beltrami CA
, Finato N, Rocco M, Feruglio GA, Puriceli C, Cigola E, Sonneblick EH, Olivetti G, Anversa P. 1995. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol27(1):291-305.
9.
Beneto A
, Gavras H, Stewart JM, Vavrck RJ, Hatinoglou S, Gavias I. 1986. Vasodepressor role of endogenous bradykinin assessed by bradykinin antagonism. Hypertension8:971-974.
10.
Berecek KH
, Zhang L. 1995. Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors. In: Mukhopadhyay AK, Raizada MK, editors. Tissue renin-angiotensin systems. New York: Plenum. p 141-168.
11.
Braget AC
, Blumenfeld J, Sealey JE. 1997. Effect of highperformance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. J Hypertens15(5):459-465.
12.
Bruckschlegel G
, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer ER, Riegger GA, Schunkert H. 1995. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension25:250-259.
13.
Buhler FR
, Laragh JH, Baer L. 1972. Propranolol inhibition of renin secretion. N Engl J Med287(24):209-214.
14.
Bursch W
, Kleine L, Tenniswood M. 1990. The biochemistry of cell death by apoptosis. Biochem Cell Biol68:1071-1074.
15.
Cambien F
, Evans A. 1995. Angiotensin I converting enzyme gene polymorphisms and coronary heart disease. Eur Heart J16(Suppl K):13-22.
16.
Cambien F
, Poirier O, Lecerf L. 1992. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature359:641-644.
17.
Campbell DJ
, Lawrence AC, Towrie A, Kladis A, Valentijin AJ. 1991. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension18:763-773.
18.
Candy GP
, Skudiky D, Mueller UK, Woodiwiss AJ, Sliwa K, Luker F, Esser J, Sareli P, Norton GR. 1999. Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. Am J Cardiol83(5):740-744.
19.
Carraway JW
, Park S, McCune SA, Holycross BJ, Radin MJ. 1999. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. J Cardiovasc Pharmacol33(3):451-460.
20.
Carretero DA
, Miyazaki S, Scicli AG. 1981. Role of kinin in the acute antihypertensive effect of the converting-enzyme inhibitor, captopril. Hypertension3:18-22.
Cody RJ
. 1994. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs7:586-598.
23.
Cody RJ
. 1995. ACE inhibitors: Myocardial infarction and congestive heart failure. Am Fam Physician52:1801-1806.
24.
Cody RJ
. 1997. The integrated effects of angiotensin II. Am J Cardiol79(5A):9-11.
25.
Csikos T
, Gallinat S, Unger T. 1997. Extrarenal aspects of angiotensin II function. Eur J Endocrinol136(4):349-358.
26.
Cushman DW
, Cheung HS. 1971a. Concentration of angiotensinconverting enzyme in tissues of the rat. Biochem Biophys Acta250:261-265.
27.
Cushman DW
, Cheung HS. 1971b. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol20:1637-1648.
28.
Danser AH
, van Kats JP, Admiraal PJ. 1994. Cardiac renin and angiotensins: Uptake from plasma versus in situ synthesis. Hypertension24:37-48.
29.
Danser AH
, van Kesteren CA, Bax WA. 1997. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: Evidence of renin binding. Circulation96:220-226.
30.
de Bold AJ
, Bruneau BG, Kuroski-de Bold ML. 1996. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res37:7-18.
31.
Delacretaz E
, Nussberger J, Puchler K. 1994. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol24:479-485.
32.
Dimmeler S
, Rippmann V, Weiland U. 1997. Angiotensin II induces apoptosis of human endothelial cells: Protective effect of nitric oxide. Circ Res81(6):970-976.
33.
Dzau V
, Colucci WS, Hollenberg NK, Williams GH. 1981. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation63(3):645-651.
34.
Dzau VJ
. 1988. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation77(Suppl I): 14-113.
35.
Dzau VJ
. 1993. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med153:937-942.
36.
Dzau VJ
, Re R. 1994. Tissue angiotensin system in cardiovascular medicine: A paradigm shift. Circulation89:493-498.
37.
Fabris B
, Chen B, Pupic V, Perich R, Johnston CI. 1990. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol15(Suppl 2):S6-S13.
38.
Fogarty Y
, Fraser CG, Browning MC. 1989. Intra-and interindividual variation of serum angiotensin converting enzyme: Clinical implications. Ann Clin Biochem26:201-202.
39.
Francis GS
. 1998. Changing the remodeling process in heart failure: Basic mechanisms and laboratory results. Curr Opin Cardiol13(3):156-161.
40.
Francis GS
, Chu C. 1995. Post-infarction myocardial remodeling: Why does it happen?Eur Heart J16(Suppl N):31-36.
41.
Franken AAM
, Derkx FHM, Man In’tVeld AJ. 1990. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab71:1008-1015.
42.
Friedland J
, Silverstein E. 1976. A sensitive fluorometric assay for serum angiotensin-converting enzyme. Am J Clin Pathol66:416-424.
43.
Gerdes AM
, Capasso JM. 1995. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol27(3):849-856.
44.
Gibbons G
, Dzau VJ. 1994. The emerging concept of vascular remodeling. N Engl J Med330:1431-1438.
45.
Heinrickson RI
, Hui J, Zurcher-Neely H, Poorman RA. 1989. A structural model to explain the partial catalytic activity of human prorenin. Am J Hypertens2:367-380.
46.
Hollenberg NK
, Fisher ND, Price DA. 1998. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative interruption of the renin system. Hypertension32(3):387-392.
47.
Huttl S
, Nussberger J, Lehmann K, Hasford J, Brunner HR, Delius W. 1995. Beneficial clinical effect of very early enalapril treatment in patients with acute left ventricular failure complicating myocardial infarction. Clin Cardiol18:317-323.
48.
Inagami T
. 1999. Molecular biology and signaling of angiotensin receptors: Anoverview. J Am Soc Nephrol10(Suppl 11):S2-S7.
49.
Irwin MW
, Mak S, Mann DL, Qu R, Pennington JM, and others. 1999. Tissue expression and immunolocalization of tumor necrosis factor-alpha in post-infarcted dysfunctional myocardium. Circulation99(11):1492-1498.
50.
Kabour A
, Henegar JR, Janicki JS. 1994. Angiotensin II (AII)-induced myocyte necrosis: Role of the AII receptor. J Cardiovasc Pharmacol23:547-557.
51.
Kawaguchi H
, Kitabatake A. 1997. Alterations of signal transduction system in heart failure. Jpn Heart J38(3):317-332.
52.
Kim S
, Ohta K, Hamaguchi A. 1995. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension25:1252-1259.
53.
Kinoshita A
, Urata H, Bumpus FM, Husain A. 1993. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem266(29):19192-19197.
54.
Kokkonen JO
, Saarinen J, Kovanen PT. 1998. Angiotensin II formation in the human heart: An ACE or non-ACE-mediated pathway?Ann Med30(Suppl 1):9-13.
55.
Lainchbury JG
, Espiner EA, Frampton CM, Richards AM, Yandle TG, Nicholls MG. 1997. Cardiac natriuretic peptides as predictor of mortality. J Intern Med241:257-259.
56.
Lear W
, Ruzika M, Leenen FH. 1997. ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy. Am J Physiol273(2 Pt 2):H641-H646.
57.
Lee JA
, Liang CS, Lee MA, Lindpainter K. 1996. Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: A comprehensive study of all its components in the dog. Proc Natl Acad Sci U S A93:11035-11040.
58.
Leenen FH
, Skarda V, Yuan B, White R. 1999. Changes in cardiac ANG II postmyocardial infarction in rats: Effects of nephrectomy and ACE inhibitors. Am J Physiol276(1 Pt 2):H317-H325.
59.
Lindpaintner K
, Niedermaier N, Drexler H, Ganten D. 1992. Left ventricular remodeling after myocardial infarction: Does the cardiac renin-angiotensin system play a role?J Cardiovasc Pharmacol20(Suppl I):S41-S47.
60.
Lowes BD
, Minobe W, Abraham WT, Rizeg MN, Bohlmeyer TJ, and others. 1997. Changes in gene expression in the intact human heart. J Clin Invest100(9):2315-2324.
61.
MacFayden RJ
, Struthers AD. 1997. The practical assessment of compliance with ACE-inhibitor therapy—a novel approach. J Cardiovasc Pharmacol29(1):119-124.
62.
Madsen B
, Keller N, Christiansen E, Christensen N. 1995. Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: Comparison with clinical evaluation, ejection fraction, and exercise capacity. J Card Fail1:207-216.
63.
Maeda K
, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. 1998. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J135:825-832.
64.
Matsusaka T
, Ichikawa I. 1997. Biological functions of angiotensin and its receptors. Annu Rev Physiol59:395-412.
65.
Meggs LG
, Coupet J, Huang H, Cheng W. 1993. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res72:1149-1162.
66.
Menard J
, Guyene TT. 1995. Commentary: Renin assays: Adebate for clinicians, not only for specialists. J Hypertens13:367-369.
67.
Meng QC
, Oparil S. 1996. Purification and assay methods for angiotensin-converting enzyme. J Chromatogr A743:105-122.
68.
Moeller I
, Allen AM, Chai S-Y, Zhou J, Mendelsohn FA. 1998. Bioactive angiotensin peptides. J Hum Hypertens12:289-293.
69.
Morganti A
, Pelizzola D, Mantero F. 1995. Immunoradiometric versus enzymatic renin assay: Results of the Italian Multicenter Comparative Study. J Hypertens13:19-26.
70.
Morganti A
, Pelizzola D, Mantero F, Gazzano G. 1995. Author’s reply. J Hypertens13:31-31.
71.
Muller DN
, Fischli W, Clozel JP. 1998. Local Angiotensin II generation in the rat heart: Role of renin uptake. Circ Res82:13-20.
72.
Nahmias C
, Strosberg AD. 1995. The angiotensin AT receptor: Searching for signal-transduction pathways and function. Trends Pharmacol Sci16:223-225.
73.
Neri-Serneri GG
, Boddi M, Coppo M. 1996. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation94(8):1886-1893.
74.
Nicholls MG
, Richards AM, Agarwal M. 1998. The importance of the renin-angiotensin systems in cardiovascular disease. JHum Hypertens12(5):295-299.
75.
Nio Y
, Matsubara H, Murasawa S, Kanasaki M, Inada M. 1995. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest95:46-54.
76.
Nishimura H
, Hoffman S, Baltatu O. 1996. Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int Suppl55:S18-S23.
77.
Nussberger J
, Juillerat L, Perret F, Waeber B, Bellet M, Brunner J, Menard J. 1989. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am Heart J117:717-722.
78.
Okinishi H
, Oka Y, Shiota N. 1993. Marked species difference in the vascular angiotensin II-forming pathways: Humans versus rodents. Jpn J Pharmacol62:207-210.
79.
Olivetti G
, Abbi R, Quanini F, others. 1997. Apoptosis in the failing human heart. N Engl J Med336:1131-1141.
80.
Ou R
, Sun Y, Ganjam VK, Weber KT. 1996. In situ production of angiotensin II by fibrosed rat pericardium. J Mol Cell Cardiol28:1319-1327.
81.
Paul M
, Bachman J, Ganten D. 1992. The tissue renin-angiotensin systems in cardiovascular disease. Trends Cardiovasc Med2:94-99.
82.
Pfeffer MA
, Braunwald E. 1990. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation81:1161-1172.
83.
Pfeffer MA
, Braunwald E, Moye LA, Basta L, Brow EJ, Cuddy TE. 1992. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction—Results of the survival and ventricular enlargement trial. N Engl J Med327:669-677.
84.
Pfeufer A
, Osterziel KF, Urata H, Borck G, and others. 1996. Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Am J Cardiol78:362-364.
85.
Pinto JE
, Viglione P, Saavedra JM. 1991. Autoradiographic localization and quantification of rat heart angiotensin converting enzyme. Am J Hypertens4:321-326.
86.
Pinto YM
, Buikema H, van Gilst WH, Lie KI. 1996. Activated tissue renin-angiotensin systems add to the progression of heart failure. Basic Res Cardiol2:85-90.
87.
Pitt B
, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. 1997. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet349(9054):747-752.
88.
Plouin PF
, Cudek P, Arnal JF, Guyene TT, Corvol P. 1990. Immunoradiometric assay of active renin versus determination of plasma renin activity in the clinical investigation of hypertension, congestive heart failure, and liver, cirrhosis. Horm Res34:138-141.
89.
Raynolds MV
, Perryman MB. 1995. The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease. Eur Heart J16(Suppl K):23-30.
90.
Remme WJ
. 1998. Effect of ACE inhibition on neurohormones. Eur Heart J19(Suppl J):J16-J23.
91.
Rouleau JL
, Moye LA, Champlain J. 1991. Activation of neurohormonal systems following acute myocardial infarction. Am J Cardiol80D-86D.
92.
Rouleau JL
, Packer M, Moye L, Champlain J, and others. 1994. Prognostic value of neurohormonal activation in patients with an acute myocardiac infarction: Effect of Captopril. J Am Coll Cardiol24(3):583-591.
93.
Rousseau MF
, Konstram MA, Bendict CR. 1994. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensinconverting enzyme inhibitor. Am J Cardiol73:488-493.
94.
Ryan US
, Ryan JW, Whitaker C, Chiu A. 1975. Localization of angiotensin converting enzyme (kininase II): Immunocytochemistry and immunofluorescence. Tissue Cell8:125-145.
95.
Sagnella GA
. 1998. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Colch)95(5):519-529.
96.
Sancho J
, Re RN, Burton J, Barger CA, Haber E. 1976. Role of the renin-angiotensin system in cardiovascular homeostasis in normal human subjects. Circulation53:400-405.
97.
Sealey J
, Laragh J. 1977. How to do a plasma renin assay. Cardiovasc Med2:1079-1092.
Sealey JE
. 1991. Plasma renin activity and plasma prorenin assays. Clin Chem37(10):1811-1819.
100.
Sealey JE
, Gerten-Banes J, Laragh J. 1972. The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int1:240-251.
101.
Sealey JE
, Laragh J. 1975. Radioimmunoassay of plasma renin activity. Semin Nucl Med5:189-193.
102.
Sealey JE
, Laragh JH. 1996. Renin and prorenin: Advances and declines in methodology. Clin Chem42(7):993-994.
103.
Sealey JE
, Moon C, Laragh JH, Atlas SA. 1977. Plasma prorenin in normal, hypertensive, and anephric subjects and its effect on renin measurements. Circ Res40(Suppl I):41-45.
104.
Sealey JE
, Rubatto S. 1989. Prorenin and renin as separate mediators of tissue and circulating systems. Am J Hypertens2:358-366.
105.
Sealey JE
, Trenkwalder P, Gahnem F, Catanzaro D, Laragh JH. 1994. Plasma renin methodology: Inadequate sensitivity and accuracy of direct renin assay for clinical applications compared with the traditional enzymatic plasma renin activity assay. J Hypertens13:27-30.
106.
Sechi LA
, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. 1992. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res71:1482-1489.
107.
Simon D
, Hartmann DJ, Badouaille G. 1992. Two-site directed immunoassay specific for active renin. Clin Chem38(10): 1959-1962.
108.
Skidgel RA
, Erdos EG. 1987. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp HypertensA9:243-260.
109.
St. John Sutton M
, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G. 1997. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictor and impact of long-term use of captopril: Information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation96(10):3294-3299.
110.
Stoll M
, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. 1995. The angiotensin AT 2-recpeotrmediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest95:651-657.
111.
Studer R
, Reinecke H, Muller G, Holtz J, Just H, Drexler H. 1994. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest94:301-310.
112.
Studies of Left Ventricular Dysfunction Investigators
. 1991. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med325(5):293-302.
113.
Studies of Left Ventricular Dysfunction Investigators
. 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med327(10):685-691.
114.
Sun Y
. 1997. Local angiotensin II and myocardial fibrosis. Adv Exp Med Biol432:55-61.
115.
Sun Y
, Ramires FJ, Zhou G, Ganjam VK, Weber KT. 1997. Fibrous tissue and angiotensin II. J Mol Cell Cardiol29(8):2001-2012.
116.
Sun Y
, Weber K. 1996. Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Cardiovasc Res518-525.
117.
Suzuki J
, Matsubara H, Urakami M, Inada M. 1993. Rat angiotensin II (type 1A) receptor m RNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res73:439-447.
118.
Swedberg K
, Eneroth P, Kjekshus J, Snapinn S. 1990. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (Follow-up of the CONSENSUS trial). Am J Cardiol66:40D-45D.
119.
Swedberg K
, Eneroth P, Kjekshus J, Wilhelmsen L. 1990. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation82:1730-1736.
120.
Swedberg K
, Kjekshus J. 1987. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med316(23):1429-1435.
121.
Tan LB
, Jalil JE, Pick R. 1991. Cardiac myocyte necrosis induced by angiotensin II. Circ Res69(5):1185-1195.
122.
Thomson GJ
, Berry A. 1996. Choice of assay or detection method. In: Price NC, editor. Proteins Lab Fax. Oxford, UK: Bios Scientific, Academic Press. p 1-13.
123.
Timmermans PB
, Wong PC, Chiu AT, Herblin WF. 1993. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev45:205-251.
124.
Trenkwalder P
, James GD, Laragh JH, Seaaley JE. 1996. Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age. Am J Hypertens9(7):621-626.
125.
Tsutsumi Y
, Matsubara H, Ohkubo N. 1998. Angiotensin II type 2 receptor is unregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res83(10):1035-1046.
126.
Urata H
, Kinoshita A, Misona KS, Bumpus FM, Husain A. 1990. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem265(36):22348-22357.
127.
Urata H
, Nishimura H, Ganten D. 1995. Mechanisms of angiotensin II formation in humans. Eur Heart J16(Suppl N):79-85.
128.
Vancura V
, Hubacek J, Malek I, Gebauerova M, Pitha J, and others. 1999. Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?Am J Cardiol83(3):461-462.
129.
Villareal FJ
, Kim NN, Ungab GD, Printz MP, Dillman WH. 1993. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation88:2849-2861.
130.
Weber KT
, Sun Y, Cleutjens JM. 1995. Structural remodeling of the myocardium postinfarction: Potential mechanisms and influence of therapy. Cardiol Rev3:53-65.
131.
Weber MA
, Neutel JM, Smith DG. 1992. Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition. Am Heart J123:1414-1420.
132.
White M
, Weichmann RL, Roden MB, Hagan MM, Wollmering JD, and others. 1995. Cardiac •-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: Evidence for catecholamine-mediated myocardia damage. Circulation92:2183-2189.
133.
Wolf K
, Bruna R, Bruckschlegel G, Schunkert H, Riegger GA, Kurtz A. 1996. Angiotensin II receptor gene expression in hypertrophied left ventricles of rat hearts. J Hypertens14(3):349-354.
134.
Wolny A
, Clozel JP, Rein J. 1997. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res80:219-227.
135.
Zisman LS
, Asano K, Dutcher DL. 1998. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation98(17):1735-1741.
136.
Zuo WM
, Pratt RE, Heusser CH, Bews JPA, deGasparo M, Dzau VJ. 1992. Characterization of a monoclonal antibody specific for human active renin. Hypertension19:249-254.
